Compare Natera Inc. Common Stock (NTRA) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SoFi Technologies Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while SoFi Technologies Inc trades at $14.06 (market cap $19.68B). The key difference: Natera Inc. Common Stock is far larger — about 2.9× SoFi Technologies Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SoFi Technologies Inc for 60 Days on average.
| NTRA | SOFI | |
|---|---|---|
Market Cap | $57.03B | $19.68B |
Volume | 1,131,157 | 30,790,556 |
Sector | Health | Financials |
52-Week High | $425.64 | $32.21 |
52-Week Low | $179.42 | $14.22 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $56.18B | $19.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SoFi Technologies stock trades at $14.22, down 6.63% with bearish technical signals. The company shows strong revenue growth from $2.6B in 2024 to $3.6B in 2025, with consistent earnings beats. However, negative operating cash flow and high P/E ratio of 31.1 present valuation concerns. Recent news highlights SoFi's stablecoin initiatives and record loan originations while the stock faces pressure from rising yields.
SoFi offers growth potential with expanding financial services but faces execution risks in a competitive fintech landscape. The stock trades at a discount to analyst consensus target of $21.08, though negative cash flow trends and market sensitivity to interest rates warrant caution. Investors should weigh strong fundamentals against technical weakness and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
